Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	23 people with Raynaud's phenomenon and systemic sclerosis In review	Withdrawals with oral nifedipine with intravenous iloprost
RCT	46 people with Raynaud's phenomenon and systemic sclerosis	Headache 100% with intravenous iloprost (given initially by infusion over 8 hours on 5 consecutive days plus one 8-hour infusion every 6 weeks) 18% with oral nifedipine (twice daily) Absolute numbers not reported	Significance not assessed
RCT	46 people with Raynaud's phenomenon and systemic sclerosis	Hypotension 14% with intravenous iloprost (given initially by infusion over 8 hours on 5 consecutive days plus one 8-hour infusion every 6 weeks) 29% with oral nifedipine (twice daily) Absolute numbers not reported	Significance not assessed
RCT	46 people with Raynaud's phenomenon and systemic sclerosis	Withdrawals 6 people with (given initially by infusion over 8 hours on 5 consecutive days plus one 8-hour infusion every 6 weeks) 5 people with oral nifedipine (twice daily)	Significance not assessed